CINECA IRIS Institutional Research Information System

PIGA, Antonio Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.066
EU - Europa 3.878
AS - Asia 1.897
AF - Africa 61
SA - Sud America 18
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 10.944
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.972
CN - Cina 1.006
IT - Italia 587
IE - Irlanda 567
SE - Svezia 540
UA - Ucraina 476
DE - Germania 427
FR - Francia 379
FI - Finlandia 312
SG - Singapore 265
VN - Vietnam 200
KR - Corea 188
GB - Regno Unito 175
DK - Danimarca 123
PL - Polonia 103
CA - Canada 87
IN - India 73
GR - Grecia 38
KE - Kenya 36
AT - Austria 34
JP - Giappone 25
TR - Turchia 24
BE - Belgio 22
NL - Olanda 21
TH - Thailandia 18
CH - Svizzera 16
EG - Egitto 16
ID - Indonesia 16
BR - Brasile 14
CZ - Repubblica Ceca 14
RU - Federazione Russa 13
AU - Australia 11
ES - Italia 10
TW - Taiwan 10
IR - Iran 9
JO - Giordania 9
PK - Pakistan 9
IQ - Iraq 8
EU - Europa 7
LB - Libano 7
MX - Messico 7
RO - Romania 7
HK - Hong Kong 6
CY - Cipro 5
NO - Norvegia 5
PT - Portogallo 4
A1 - Anonimo 3
DZ - Algeria 3
MY - Malesia 3
SY - Repubblica araba siriana 3
UZ - Uzbekistan 3
LA - Repubblica Popolare Democratica del Laos 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
BG - Bulgaria 1
CL - Cile 1
ET - Etiopia 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
MU - Mauritius 1
MV - Maldive 1
PS - Palestinian Territory 1
SN - Senegal 1
YE - Yemen 1
Totale 10.944
Salva come PNG Salva come JPEG
Città #
Beijing 728
Chandler 719
Dublin 566
Ann Arbor 336
Houston 333
Jacksonville 290
Villeurbanne 274
Fairfield 243
Torino 199
Singapore 192
Princeton 189
Medford 182
Ashburn 176
Wilmington 172
Nyköping 170
Dong Ket 154
Woodbridge 127
Dearborn 107
Guangzhou 107
Cambridge 103
Warsaw 103
Seattle 100
Boston 78
Boardman 57
Milan 51
Fremont 46
Redwood City 44
Pisa 38
Toronto 36
Vienna 34
Verona 33
Falls Church 30
Athens 29
San Mateo 28
Turin 28
Norwalk 27
Pune 23
Lachine 22
New York 22
Hefei 21
Santa Clara 21
Brussels 19
Rome 18
Los Angeles 15
Nanjing 15
Brno 13
Nairobi 12
Jinan 11
Nanchang 11
Munich 10
Kunming 9
Moscow 9
Chengdu 8
Fuzhou 8
Hebei 8
Helsinki 8
London 8
Mountain View 8
San Mauro Torinese 8
Shanghai 8
Wuhan 8
Bangkok 7
Des Moines 7
Redmond 7
San Diego 7
Silver Spring 7
Taipei 7
Amman 6
Cairo 6
Detroit 6
Düsseldorf 6
Jakarta 6
Nanning 6
Ottawa 6
Salt Lake City 6
Zhengzhou 6
Bologna 5
Limassol 5
Phoenix 5
Scranton 5
Upper Marlboro 5
Auburn Hills 4
Central District 4
Chennai 4
Collegeville 4
Esslingen am Neckar 4
Frankfurt am Main 4
Genoa 4
Hangzhou 4
Hanover 4
Lissone 4
Malappuram 4
New Delhi 4
Nürnberg 4
Perugia 4
Spin 4
Stockholm 4
Tampa 4
Tappahannock 4
Tokyo 4
Totale 6.649
Salva come PNG Salva come JPEG
Nome #
Atrial fibrillation in β-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options 277
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia 225
Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: A multicentre nationwide study 2000-12 197
Challenges of blood transfusions in β-thalassemia 197
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. 194
Effectiveness of bibliographic searches performed by paediatric residents and interns assisted by librarians. A randomised controlled trial 194
A child with hyperferritinemia: case report 184
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment 184
Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major 178
Rare Genetic Anemias Due to Defective Iron Recycling: Aceruloplasminemia and Type 4 Hemochromatosis 169
Role of pharmacogenetics on deferasirox AUC and efficacy 163
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia 160
A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). 149
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload 137
Seventy-five genetic loci influencing the human red blood cell 137
Modalità di intervento del neuropschiatra infantile all'interno del day-hospital per bambini talassemisi 124
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children 117
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with b-thalassemia 115
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs 114
Il bibliotecario formatore e la ricerca bibliografica guidata: uno studio randomizzato controllato 114
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 103
Impact of bone disease and pain in thalassemia 103
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 103
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major 100
Clinical relevance of the assessment of deferasirox trough levels in thalassemia patients 97
The European Hematology Association roadmap for European Hematology Research: A consensus document 97
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 93
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients 90
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients 88
A newly-characterized alpha-thalassaemia-1 deletion removes the entire alpha-like globin gene cluster in an Italian family. 87
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness. 85
Deferasirox AUC efficacy cutoff and role of pharmacogenetics 85
DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY IN THE ASSESSMENT OF SIGNIFICANT LIVER FIBROSIS IN PAEDIATRIC LIVER TRANSPLANT RECIPIENTS 84
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4 83
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia 83
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine 83
Epigenetic therapy for Friedreich ataxia. 82
Pyrimidine 5'-nucleotidase acquired deficiency in beta-thalassemia: involvement of enzyme-SH groups in the inactivation process. 82
Anemie ” eds, McGraw-Hill, Milano 1998, p 95-133. 82
A multi-center safety trial of the oral iron chelator deferiprone. 80
Exercise Stress Echocardiography with Tissue Doppler Imaging (TDI) Detects Early Systolic Dysfunction in Beta-Thalassemia Major Patients without Cardiac Iron Overload 77
Deferiprone: New insight 77
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness 76
Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. 75
Assessing the efficacy of EBM teaching in a clinical setting 74
Clinical relevance of deferasirox trough levels in β-thalassemia patients 74
A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload 73
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian Webthal project. 72
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 72
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. 71
A new fast-moving variant causing erythrocytosis and mild hemolysis: Hb Gàmbara [beta 82(EF6)Lys-->Glu] 68
Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. 67
Blood pressure and heart rate in young thalassemia major patients. 67
Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. 67
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia 67
Correlation between transfusion requirement, blood volume and haemoglobin level in homozygous beta-thalassaemia. 66
Revisiting nephrocalcinosis: A single-center perspective 66
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. 65
Combined use of oral chelators and desferrioxamine in thalassemia 65
Bone density and metabolism in thalassaemia. 64
Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait 64
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study 63
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 63
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring 63
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 62
Reduction of hepatic insulin extraction induced by iron overload and hyperinsulinemia in insulin-resistant homozygous beta thalassemic pubertal children 61
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. 61
Survival and disease complications in thalassemia major. 61
Early iron overload in beta-thalassaemia major: when to start chelation therapy? 60
Hb Trento: an elongated C-terminal beta chain due to a new frameshift mutation [beta144 (-A)]. 60
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation 60
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry 59
New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. 59
Behaviour of myeloid precursors in homozygous beta thalassaemia. 59
The Molecular Spectrum of β- and α-Thalassemia Mutations in Non-Endemic Umbria, Central Italy 59
Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity 59
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver 58
Transient elastography for non-invasive evaluation of post-transplant liver graft fibrosis in children 57
Survival in thalassemia with conventional treatment. 55
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. 55
Comparison of clinical expression of type 2 (juvenile) and type 3 hemochromatosis. RID B-1183-2008 54
Complete recovery from paraparesis in spinal cord compression due to extramedullary haemopoiesis in beta-thalassaemia by emergency radiation therapy. 54
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial 54
Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent 54
Comparison of clinical expression of type 2 (juvenile) and type 3 hemochromatosis. RID B-1183-2008 54
Iron overload and antioxidant status in patients with beta-thalassemia major. 53
High-dose desferrioxamine as a cause of growth failure in thalassemic patients 53
Screening of beta-thalassemia mutations by PCR and ASO analysis in an Italian population of mixed geographic origin. 52
Worsening of myocardial performance index in beta-thalassemia patients despite permanently normal iron load at MRI: A simple and cheap index reflecting cardiovascular involvement? 52
Deferiprone 52
Severe iron overload in Blackfan-Diamond anemia: a case-control study 52
HEPATO-SPLENIC SCINTIGRAPHY IN CHILDREN WITH BETA-THALASSEMIA (LA SCINTIGRAFIA EPATO-SPLENICA IN BAMBINI CON B-TALASSEMIA) 52
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 51
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection 51
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. 50
Cirrhosis associated with multiple transfusions in thalassaemia 49
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 49
Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2) 49
Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. 48
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia 48
Totale 8.751
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.272
article - articoli 0
book - libri 0
conference - conferenze 2.492
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.764
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.460 0 0 100 116 120 310 203 101 158 136 149 67
2020/20211.650 120 56 208 66 212 92 142 41 196 116 107 294
2021/20221.532 54 82 79 119 63 78 103 96 47 119 291 401
2022/20232.237 254 169 51 193 209 639 188 135 221 43 91 44
2023/2024830 119 157 43 57 49 79 19 53 1 55 56 142
2024/2025212 41 155 16 0 0 0 0 0 0 0 0 0
Totale 11.447